S&P rates Pfizer notes AAA

Standard & Poor's said it assigned an AAA rating to Pfizer Inc.'s €900 million 4¾% senior unsecured notes due 2014.

Proceeds will be used for general corporate purposes.

The agency said Pfizer continues to maintain a very conservative financial profile and generates strong free cash flows and, as such, the recent debt issuance does not have a material impact on Pfizer's financial ratios.

The ratings on Pfizer reflect the company's excellent position in the pharmaceutical market, highlighted by its diverse drug portfolio, well-stocked product pipeline and huge research and development program, and the company's very conservative financial policies and superior financial profile.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.